Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $20.83

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.83.

A number of equities research analysts recently commented on the company. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Altimmune in a report on Tuesday, March 18th. Finally, Stifel Nicolaus initiated coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the stock in a transaction on Thursday, March 13th. The stock was purchased at an average price of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at approximately $52,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Larson Financial Group LLC acquired a new position in Altimmune in the third quarter valued at about $31,000. SBI Securities Co. Ltd. bought a new stake in shares of Altimmune in the 4th quarter valued at about $45,000. Virtus ETF Advisers LLC acquired a new stake in shares of Altimmune in the 4th quarter valued at approximately $60,000. Cullen Frost Bankers Inc. bought a new position in Altimmune during the 4th quarter worth approximately $72,000. Finally, Sunbelt Securities Inc. grew its holdings in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock valued at $79,000 after purchasing an additional 8,470 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $5.89 on Friday. Altimmune has a 52-week low of $5.14 and a 52-week high of $11.16. The business has a fifty day moving average of $6.31 and a two-hundred day moving average of $7.08. The stock has a market cap of $453.61 million, a PE ratio of -3.80 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Analysts predict that Altimmune will post -1.35 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.